Skip to main content

Table 2 Inclusion and exclusion criteria

From: Mapping evidence on the effects of gender-affirming hormone therapy on the hard and soft tissues of the craniofacial complex in transgender people: a protocol for a scoping review

Item Inclusion criteria Exclusion criteria
Participants • Transgender people of any age, demographics, ethnic or socioeconomic status, and with a good medical and dental health status.
• Both self-identified transgender people and those diagnosed by health professionals will be eligible.
• Any term used to define transgender people will be eligible under the condition that these terms were defined by the authors and were covered by the definition for gender incongruence [3] or the umbrella definition of transgender people [1] listed in Table 1. Examples of such terms include transgender, transgender persons, trans persons, trans people, trans men, trans women, transgendered persons, transsexual persons, persons with gender dysphoria, persons with gender identity disorder, female-to-male persons, male-to-female persons, and persons with gender incongruence.
• Transgender people with congenital anomalies such as cleft lip and palate
• Transgender people that underwent previous or concomitant craniofacial (e.g., plastic orthognathic) surgery
Interventions • GAHs of any type, dosage, and administered through any type of route.
• Interventions with GAHs refer to the administration of hormones such as testosterone, androgens, estrogens, estradiol, and antiandrogens.
• Eligible synonyms of GAH therapy include cross-sex hormone therapy, hormone-replacement therapy, gender-confirming hormone therapy, and transgender hormone therapy.
• Administration of GAHs for at least 3 months.
• GAH therapy combined with other craniofacial interventions, e.g., plastic or orthognathic surgery
• GAH administration that was not supervised by health professionals
Outcomes • Any type of quantitative or qualitative outcome of the hard or soft tissues of the craniofacial complex. We will apply the following definition for “craniofacial”: “relating to or involving the cranium or the face or both” (Table 1).
• Any type of qualitative or quantitative consequences of changes in the craniofacial complex as a result of GAH therapy in transgender people.
• Outcomes associated with hair growth and dermatologic conditions such as acne
Time point • Outcomes measured after at least 3 months of administration of GAHs.  
Setting • Any type of setting, e.g., university or private practice setting.  
Sources of evidence • Observational studies, i.e., exploratory, descriptive, and analytical studies.
• Experimental studies, i.e., randomized trials.
• Qualitative studies.
• Mixed method studies.
• Systematic reviews, guidelines, editorials, viewpoints, expert opinions, commentaries, and animal studies
Language • Any language.  
Publication status • Only peer-reviewed manuscripts will be eligible.  
Publication dates • Published from inception onwards.